Vertex Pharmaceuticals continues to perform well on all fronts

American biopharma company Vertex Pharmaceuticals (Nasdaq: VRTX) has announced strong third quarter 2023 financial results and raised its guidance for product revenues in 2023.

Revenues came in at $2.48 billion, a 6% increase compared from the same period of 2022, primarily driven by the strong performance of cystic fibrosis med Trikaftra (elexacaftor/tezacaftor/ivacaftor).

On a generally accepted accounting principles (GAAP) and non-GAAP basis, net income increased by 11% and 2%, respectively, to $1.04 billion.